This forum aims to share insights on biosimilar tendering across Europe, with the objective of identifying learnings that can be leveraged to support sustainable tender practices and biosimilar competition. This forum emerges in the sequence of relevant topics highlighted in the ISPOR Science Strategy and the Biosimilars Special Interest Group, by aiming to adress healthcare system inefficiencies in terms of biosimilar procurement. While biological medicines have changed the course of many complex conditions, their high cost challenges healthcare budgets around the globe. Enhancing competition in the biological medicines market, by introducing biosimilars, offers a timely opportunity for healthcare systems to address inefficiencies, by lowering treatment costs, and possibly facilitating broader access to patients. Procurement mechanisms are of specific interest in the context of establishing sustainable biosimilar competition market dynamics, as these can have an important impact on biosimilar uptake, price dynamics and competitor concentration. A careful design of procurement mechanisms, and discussion on what this exactly entails, is needed. The tender landscape for biosimilars varies considerably across Europe and settings, and offers the opportunity to derive learnings and best practices. As a result, this forum will present an insightful multi-stakeholder exchange not only on learnings and opportunities from current practices, but also on key recommendations for an optimal tender design, to guarantee long term competition and access of biosimilars to patients. The Forum will follow the structure of a panel, with 10 minutes of the session reserved for Q&A with the Forum attendees. Catarina Lopes Pereira will moderate the session. Liese Barbier will share pan-European insights on biosimilar tender practices from the academic perspective. Jackie Vanderpuye-Orgle will provide an overview of industry considerations for fostering a sustainable biosimilars market. Ilan Akker will provide insights from the Dutch competition authority perspective, drawing from the findings of their recent sector enquiry.